JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.
Phase 2 small_molecule active
Quick answer
JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion. for Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI. is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active